J07BF03 - Poliomyelitis, Trivalent, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the poliomyelitis, trivalent, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated polio virus type 1, 2 and 3.
Therapeutic characteristics
The poliomyelitis vaccine is indicated for the active immunization against poliomyelitis in infants, children and adults, for both primary immunization (2 or 3 doses) and for following booster doses. It is administered by intramuscular or deep subcutaneous injection.
Metabolism and pharmacokinetics
The poliomyelitis vaccine is not metabolized by the cytochrome P450 system.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Imovax Polio. (Last edition: 31.06. 2014). #1879
Similar drugs
© NAPOS 2024